CSL (ASX:CSL): Can Restructuring and Cost Savings Support a Recovery?

Aditi Sarkar

29 July 2026 10:40 PM AEST

CSL (ASX:CSL): Can Restructuring and Cost Savings Support a Recovery?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

First-half revenue declined 4% in constant currency to USD 8.3 billion.
Underlying NPATA fell 7% to USD 1.9 billion, while statutory NPAT dropped 81% to USD 401 million.
Management revised FY26 guidance to about USD 15.2 billion in revenue and USD 3.1 billion in underlying NPATA.
CSL expects USD 500–550 million in annualised pre-tax savings by FY28.

CSL Limited (ASX:CSL) is attempting to stabilise earnings after guidance cuts, restructuring charges and a delayed Seqirus demerger. Cost reductions and resilient cash generation provide support, but weaker Behring revenue, vaccine-market uncertainty and major Vifor impairments keep the recovery case unsettled.

Three Businesses Shape CSL

CSL Behring produces plasma-derived therapies, CSL Seqirus supplies influenza vaccines and CSL Vifor focuses on iron deficiency and nephrology. CSL reports its financial results in US dollars.

Restructuring Changes the Group

CSL announced a net workforce reduction of up to 15%, closure of 22 underperforming US plasma centres and a USD 750 million buy-back. The proposed Seqirus demerger was delayed indefinitely because of volatility in the US influenza vaccine market.

Paul McKenzie departed as chief executive in February 2026, with Gordon Naylor appointed interim CEO.

First-Half Earnings Weaken

For the half ended 31 December 2025, revenue fell 4% in constant currency to USD 8.3 billion. Underlying NPATA declined 7% to USD 1.9 billion and statutory NPAT fell 81% to USD 401 million.

Behring revenue declined 7%, including a 27% fall in albumin sales and a 6% decline in immunoglobulins. Seqirus revenue eased 2%, while Vifor increased 12%.

Cash Flow and Savings Provide Support

Operating cash flow increased 3% to USD 1.3 billion, and CSL maintained a USD 1.30 interim dividend. Management stated that about 60% of targeted FY26 savings had been secured and expects USD 500–550 million in annualised pre-tax savings by FY28.

FY26 guidance was reduced to about USD 15.2 billion in revenue and USD 3.1 billion in underlying NPATA. CSL also flagged roughly USD 5 billion of non-cash pre-tax impairments across FY26 and FY27.

What May Be Watched Next

The FY26 result, Behring volumes, cost savings, permanent CEO appointment and any revised Seqirus plan may indicate whether earnings are stabilising.

Key Risks

Repeated guidance cuts have weakened execution confidence. Vaccine demand, China policy changes, Vifor impairments, currency movements and unsettled leadership remain material uncertainties.

What are CSL’s main businesses?

CSL Behring, CSL Seqirus and CSL Vifor.

What is CSL’s revised FY26 revenue guidance?

Management guided revenue of about USD 15.2 billion.

How much annualised saving is targeted?

CSL expects USD 500–550 million in annualised pre-tax savings by FY28.

Is the Seqirus demerger proceeding?

The proposed demerger was delayed indefinitely, with no firm revised date.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.